Disproportionality analysis of falls associated with androgen receptor pathway inhibitors using the FDA adverse event monitoring system

Background Falls are a safety concern during androgen receptor pathway inhibitor (ARPI) treatment for prostate cancer, but post-marketing pharmacovigilance studies specifically focused on fall events remain limited. This study aimed to evaluate disproportionality in fall reporting for four ARPIs: abiraterone, enzalutamide, apalutamide, and darolutamide. Methods We conducted a pharmacovigilance study using individual case safety reports (ICSRs) for males aged ≥50 years reported during the common reporting window of 2019Q3–2026Q2 in the FDA Adverse Event Monitoring System (AEMS) database. Signals of disproportionate reporting in the primary analysis were detected using the reporting odds ratio (ROR) and information component (IC). Signal consistency was examined through subgroup analyses, sensitivity analyses, and multivariable logistic regression analysis. An exploratory statistical interaction screen based on drug co-reporting was conducted, and time-to-onset patterns were evaluated separately. Results In the primary analysis, enzalutamide (ROR: 2.47, 95% CI: 2.21–2.75; IC 025 : 1.09), apalutamide (ROR: 1.59, 95% CI: 1.35–1.88; IC 025 : 0.41), and abiraterone (ROR: 1.47, 95% CI: 1.30–1.65; IC 025 : 0.36) met the predefined signal criteria, whereas darolutamide did not (ROR: 1.25, 95% CI: 0.96–1.63; IC 025 : −0.08). Enzalutamide met signal criteria in all four sensitivity analyses; apalutamide and abiraterone did not meet them under indication restriction, and darolutamide met them only when secondary-suspect reports were included. Adjusted analyses supported enzalutamide (aROR: 1.47, 95% CI: 1.31–1.65) and apalutamide (aROR: 1.23, 95% CI: 1.03–1.47), but not abiraterone or darolutamide. No evaluated ARPI-docetaxel or ARPI-PARP inhibitor combination met the predefined Ω signal criterion (Ω 025 > 0). However, Fall co-reports were sparse (0–10 per combination), limiting interpretation of these findings. Non-detection of an Ω signal should not be taken as evidence that clinically relevant interactions are absent. Median time to onset was 64 days for enzalutamide, 74 days for apalutamide, and 205 days for abiraterone, with early-failure patterns in Weibull analyses. Conclusion The enzalutamide and apalutamide signals reproduced previously documented Fall associations, whereas the abiraterone and darolutamide findings varied across analysis conditions. These findings should be interpreted as pharmacovigilance signals that may help prioritize fall-related safety concerns, rather than as direct estimates of clinical risk.

Authors

Institutions

Publication Details

Journal
Frontiers in Medicine
Published
2026-11-17
DOI
https://doi.org/10.3389/fmed.2026.1932485
Primary Topic
Pharmacovigilance and Adverse Drug Reactions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Disproportionality analysis of falls associated with androgen receptor pathway inhibitors using the FDA adverse event monitoring system

Hua Ho, Haicheng Wang, Rongyao Liu, Tao Liu
5 links
Frontiers in Medicine
Pharmacovigilance and Adverse Drug Reactions
article

Disproportionality analysis of falls associated with androgen receptor pathway inhibitors using the FDA adverse event monitoring system

Hua Ho, Haicheng Wang, Rongyao Liu, Tao Liu
article en

Abstract

Background Falls are a safety concern during androgen receptor pathway inhibitor (ARPI) treatment for prostate cancer, but post-marketing pharmacovigilance studies specifically focused on fall events remain limited. This study aimed to evaluate disproportionality in fall reporting for four ARPIs: abiraterone, enzalutamide, apalutamide, and darolutamide. Methods We conducted a pharmacovigilance study using individual case safety reports (ICSRs) for males aged ≥50 years reported during the common reporting window of 2019Q3–2026Q2 in the FDA Adverse Event Monitoring System (AEMS) database. Signals of disproportionate reporting in the primary analysis were detected using the reporting odds ratio (ROR) and information component (IC). Signal consistency was examined through subgroup analyses, sensitivity analyses, and multivariable logistic regression analysis. An exploratory statistical interaction screen based on drug co-reporting was conducted, and time-to-onset patterns were evaluated separately. Results In the primary analysis, enzalutamide (ROR: 2.47, 95% CI: 2.21–2.75; IC 025 : 1.09), apalutamide (ROR: 1.59, 95% CI: 1.35–1.88; IC 025 : 0.41), and abiraterone (ROR: 1.47, 95% CI: 1.30–1.65; IC 025 : 0.36) met the predefined signal criteria, whereas darolutamide did not (ROR: 1.25, 95% CI: 0.96–1.63; IC 025 : −0.08). Enzalutamide met signal criteria in all four sensitivity analyses; apalutamide and abiraterone did not meet them under indication restriction, and darolutamide met them only when secondary-suspect reports were included. Adjusted analyses supported enzalutamide (aROR: 1.47, 95% CI: 1.31–1.65) and apalutamide (aROR: 1.23, 95% CI: 1.03–1.47), but not abiraterone or darolutamide. No evaluated ARPI-docetaxel or ARPI-PARP inhibitor combination met the predefined Ω signal criterion (Ω 025 > 0). However, Fall co-reports were sparse (0–10 per combination), limiting interpretation of these findings. Non-detection of an Ω signal should not be taken as evidence that clinically relevant interactions are absent. Median time to onset was 64 days for enzalutamide, 74 days for apalutamide, and 205 days for abiraterone, with early-failure patterns in Weibull analyses. Conclusion The enzalutamide and apalutamide signals reproduced previously documented Fall associations, whereas the abiraterone and darolutamide findings varied across analysis conditions. These findings should be interpreted as pharmacovigilance signals that may help prioritize fall-related safety concerns, rather than as direct estimates of clinical risk.

Frontiers in MedicineVol. 13
Shanxi Medical University (CN), Luliang University (CN)
Good health and well-being
Pharmacovigilance and Adverse Drug Reactions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon